Neonatal alloimmune thrombocytopenia is a rare but potentially life threatening condition in newborns. It can cause bleeding in the brain and long-term effects. Treatment usually involves a ...

Neonatal alloimmune thrombocytopenia (NAIT) is a rare blood disorder that occurs when the maternal immune system attacks the baby's platelets, causing a low platelet count. Learn more here.

Neonatal alloimmune thrombocytopenia (NAIT) is a rare yet potentially life‐threatening condition caused by maternal sensitisation to fetal platelet antigens, most notably human platelet antigen 1a.

Logan diagnosed with Neonatal Alloimmune Thrombocytopenia after aunt searched symptoms on the internet; By CLAIRE BATES . Published: 07:45 EDT, 11 July 2012 | Updated: 07:49 EDT, 11 July 2012 .

BioWorld Content on 'fetal and neonatal alloimmune thrombocytopenia' Due to launch in the second half of this year, Rallybio Inc.’s phase I/II study testing RLYB-211 for prevention of fetal and ...

Neonatal Alloimmune Thrombocytopenia, or NAIT, affects one in every 5,000 pregnancies nationally WellSpan sees only one or two cases each year York family wants to educate and help families facing ...

Rallybio's shares slumped ahead of the opening bell Tuesday after the clinical-stage biotechnology company dropped its development program on prevention of fetal and neonatal alloimmune ...

Rallybio Corporation (NASDAQ: RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune thrombocytopenia. The data ...

Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases ...

Rallybio Corporation (NASDAQ: RLYB) says clinical proof-of-concept has been achieved in Phase 1b study for RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).